GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Takara Bio Inc (TSE:4974) » Definitions » Cyclically Adjusted PS Ratio

Takara Bio (TSE:4974) Cyclically Adjusted PS Ratio : 2.77 (As of Jun. 04, 2024)


View and export this data going back to 2004. Start your Free Trial

What is Takara Bio Cyclically Adjusted PS Ratio?

As of today (2024-06-04), Takara Bio's current share price is 円1034.00. Takara Bio's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2024 was 円373.79. Takara Bio's Cyclically Adjusted PS Ratio for today is 2.77.

The historical rank and industry rank for Takara Bio's Cyclically Adjusted PS Ratio or its related term are showing as below:

TSE:4974' s Cyclically Adjusted PS Ratio Range Over the Past 10 Years
Min: 2.56   Med: 9.45   Max: 14.83
Current: 2.74

During the past years, Takara Bio's highest Cyclically Adjusted PS Ratio was 14.83. The lowest was 2.56. And the median was 9.45.

TSE:4974's Cyclically Adjusted PS Ratio is ranked better than
66.27% of 504 companies
in the Biotechnology industry
Industry Median: 5.525 vs TSE:4974: 2.74

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

Takara Bio's adjusted revenue per share data for the three months ended in Mar. 2024 was 円114.362. Add all the adjusted revenue per share for the past 10 years together and divide 10 will get our Cyclically Adjusted Revenue per Share, which is 円373.79 for the trailing ten years ended in Mar. 2024.

Shiller PE for Stocks: The True Measure of Stock Valuation


Takara Bio Cyclically Adjusted PS Ratio Historical Data

The historical data trend for Takara Bio's Cyclically Adjusted PS Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Takara Bio Cyclically Adjusted PS Ratio Chart

Takara Bio Annual Data
Trend Mar15 Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24
Cyclically Adjusted PS Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 9.52 11.68 7.59 4.94 2.61

Takara Bio Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cyclically Adjusted PS Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 4.94 4.62 3.81 3.40 2.61

Competitive Comparison of Takara Bio's Cyclically Adjusted PS Ratio

For the Biotechnology subindustry, Takara Bio's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Takara Bio's Cyclically Adjusted PS Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Takara Bio's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Takara Bio's Cyclically Adjusted PS Ratio falls into.



Takara Bio Cyclically Adjusted PS Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PS Ratio takes the Revenue per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/S calculation. Because it considers this 10-year average, it's often referred to as the CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio.

Takara Bio's Cyclically Adjusted PS Ratio for today is calculated as

Cyclically Adjusted PS Ratio=Share Price/ Cyclically Adjusted Revenue per Share
=1034.00/373.79
=2.77

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Takara Bio's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2024 is calculated as:

For example, Takara Bio's adjusted Revenue per Share data for the three months ended in Mar. 2024 was:

Adj_RevenuePerShare=Revenue per Share/CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=114.362/107.2000*107.2000
=114.362

Current CPI (Mar. 2024) = 107.2000.

Takara Bio Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201406 39.688 98.000 43.414
201409 51.422 98.500 55.964
201412 52.501 97.900 57.488
201503 72.050 97.900 78.894
201506 47.843 98.400 52.122
201509 62.251 98.500 67.749
201512 61.861 98.100 67.599
201603 74.932 97.900 82.050
201606 52.369 98.100 57.227
201609 57.243 98.000 62.617
201612 61.836 98.400 67.366
201703 72.499 98.100 79.224
201706 52.776 98.500 57.437
201709 64.535 98.800 70.022
201712 70.755 99.400 76.307
201803 80.272 99.200 86.746
201806 73.471 99.200 79.396
201809 70.780 99.900 75.952
201812 70.738 99.700 76.059
201903 82.655 99.700 88.873
201906 71.835 99.800 77.161
201909 64.775 100.100 69.369
201912 67.333 100.500 71.822
202003 83.104 100.300 88.821
202006 57.617 99.900 61.827
202009 86.824 99.900 93.168
202012 100.950 99.300 108.981
202103 137.332 99.900 147.367
202106 126.828 99.500 136.643
202109 135.190 100.100 144.779
202112 117.161 100.100 125.471
202203 183.022 101.100 194.065
202206 117.112 101.800 123.324
202209 153.510 103.100 159.615
202212 229.363 104.100 236.193
202303 148.950 104.400 152.945
202306 76.203 105.200 77.652
202309 82.547 106.200 83.324
202312 88.178 106.800 88.508
202403 114.362 107.200 114.362

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Takara Bio  (TSE:4974) Cyclically Adjusted PS Ratio Explanation

Compared with the regular PS Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PS Ratio smoothed out the fluctuations of revenue during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PS Ratio should give similar results to regular PS Ratio.


Takara Bio Cyclically Adjusted PS Ratio Related Terms

Thank you for viewing the detailed overview of Takara Bio's Cyclically Adjusted PS Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Takara Bio (TSE:4974) Business Description

Industry
Traded in Other Exchanges
Address
Nojihigashi 7-4-38 Kusatu, Shiga, Otsu, JPN, 520-0058
Takara Bio Inc is a biotechnology company that develops gene therapy procedures. The company reports in three business segments: Bioindustry, Gene therapy, and AgriBio. Takara's bioindustry business provides research reagents, scientific instruments, and various contracted services to universities and companies around the world. The company's gene therapy business is focused on treating cancer and HIV. Its AgriBio business aims to leverage biotechnologies in the food ingredient field, including large-scale mushroom production. The vast majority of Takara's revenue is derived from its bioindustry segment.

Takara Bio (TSE:4974) Headlines

No Headlines